Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 63

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 63
---
 be purchased by a participant in a calendar year is $25,000. Six-month offering periods begin on January 1st and July 1st of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company’s common stock on the purchase dates of June 30 and December 31 (or the last trading day of an offering period). The per share purchase price is equal to 85% of the fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the year ended December 31, 2024, 114,405 shares were purchased and issued through the ESPP.The following tables contain information about the Company’s stock incentive plans at December 31, 2024:Stock Incentive PlanAwards Reserved For IssuanceAwardsIssuedAwards Available For Grant2011 Plan17,731,701 15,659,387 2,072,314 2014 Inducement Plan (1)1,525,000 1,399,893 125,107 Total19,256,701 17,059,280 2,197,421 Employee Stock Purchase PlanShares ReservedFor PurchaseSharesPurchasedShares AvailableFor PurchaseESPP1,000,000 685,071 314,929 (1) In January 2025, the board of directors approved an amendment to the 2014 Inducement Plan to authorize an additional 785,000 shares reserved for issuance.Stock-Based CompensationCompensation expense for stock options and RSUs is based on the estimated grant date fair value of an award recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for ESPP share options is based on the estimated grant date fair value of the ESPP shares and the number of shares that can be purchased as of the grant date, which is recognized as expense on a straight-line expense attribution method over the length of an offering period.The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 as follows (in thousands): Year Ended December 31, 202420232022Cost of goods sold$5,331 $5,537 $5,967 Research and development7,381 8,694 6,594 Selling, general and administrative34,857 33,664 35,531 Conting